News
New algorithm for large nonpedunculated rectal polyps
Visual analysis combined with submucosal invasive cancer risk stratification boosted the frequency of curative resection after endoscopic...
News
AGA Clinical Practice Update: Surveillance and screening in Barrett’s esophagus
Update focuses on expanded eligibility and newer techniques.
News
Immunotherapeutic target could fill unmet need in NSCLC
Phase 2 clinical trial shows consistent benefits at all levels of PD-L1 expression.
News
ICI combinations show survival benefit in advanced renal cancer
Authors of a systematic review suggest ICI combinations should be available worldwide as first-line treatment for advanced renal cancer.
News
How AI is, or will soon be, relevant in radiation oncology
Radiation oncologists at ASTRO 2022 discuss practical applications of AI, and new research findings.
News
Chronic stress, especially race related, may hasten cancer death
High allostatic load was associated with an 80% increased risk of cancer death among all study participants.
News
Third COVID booster benefits cancer patients
For the first time, researchers have quantified the benefits of boosters for COVID-19 in cancer patients.
News
Stem cell therapy strikes out in progressive MS
A retrospective study suggests no advantage of AHSCT over disease-modifying therapy in progressive MS.
News
More evidence for EBV’s role in MS
Genetic sequencing of T-cell responses suggests the possibility of an ongoing immune response.
News
GFAP may complement NfL as MS biomarker
GFAP is linked to progression while NfL is linked to inflammation.
News
Findings may be practice changing for early breast cancer patients
A radiation boost to the tumor bed during whole breast irradiation was as safe and effective as delivering the boost sequentially.
News
NfL levels might presage MS disability
A spike occurred about a year before clinical worsening.
News
ctDNA hints at esophageal cancer outcomes
Reductions in ctDNA were associated with better progression-free and overall survival.
News
Radiotherapy shows benefit in difficult liver cancer cases
SBRT combined with sorafenib led to a strong survival benefit versus sorafenib alone in a difficult to treat liver cancer.
News
Should McDonald criteria include optical nerve lesions?
Researchers come out in favor, with a caveat against misdiagnoses.